Promoted Content
Promoted Content

Find Drugs for Infections and Infectious Diseases in Preclinical Development in CANADA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Acidified nitrite,Edetate Disodium

            Therapeutic Area: Infections and Infectious Diseases Product Name: AB569

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 04, 2021

            Details:

            Paper published in the journal PloS One demonstrated that AB569 kills multi-drug resistant strains of Acinetobacter baumannii and Acinetobacter spp. bacteria.

            IMV

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DPX-COVID-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: DPX-COVID-19

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 28, 2020

            Details:

            The Company has successfully completed preclinical safety, GLP toxicology as well as immunogenicity and challenge studies confirming a favorable safety profile and potential for the long duration of antibody titers and protection against SARS-CoV-2.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ivermectin

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 24, 2020

            Details:

            To support the patent examination request, the Company has provided the USPTO with new formulation analyses of different diluted concentrations of its Quicksol Ivermectin in solution, data that the company had fast-tracked for completion and validation by a third-party CRO.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVAC-2

            Therapeutic Area: Infections and Infectious Diseases Product Name: COVAC-2

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Vaccine Formulation Institute

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 22, 2020

            Details:

            The authorization from Health Canada enables the Canadian Center for Vaccinology (CCfV) in Halifax to begin recruiting volunteers for the first Phase 1 clinical trial of COVAC-2 vaccine.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATI-1701

            Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1701

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Defense Threat Reduction Agency

            Deal Size: $6.3 million Upfront Cash: Undisclosed

            Deal Type: Funding October 27, 2020

            Details:

            Agreement with Ology Bioservices and a $6.3MM DTRA contract enable next stage of manufacturing and development for world’s first vaccine to prevent F. tularensis, a potential biological weapons threat.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Apabetalone

            Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 26, 2020

            Details:

            Apabetalone was shown to inhibit expression of Angiotensin-converting enzyme 2 (ACE2), the receptor utilized by the novel coronavirus to enter human cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LCTG-001

            Therapeutic Area: Infections and Infectious Diseases Product Name: LCTG-001

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Icahn School of Medicine

            Deal Size: $2.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration October 14, 2020

            Details:

            Lactiga entered a collaboration agreement with the Icahn School of Medicine at Mount Sinai to advance preclinical research into LCTG-001 as a potential treatment for COVID-19 patients. Partners secured an NIH R01 Emergency Award of over $2MM to advance this study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VBI-2901

            Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2901

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: VBI Vaccines

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 18, 2020